Voloridge Investment Management
DNTH icon

Voloridge Investment Management’s Dianthus Therapeutics DNTH Stock Holding History

Voloridge Investment Management’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-39,480
Closed -$1.63M – 1075
2025
Q4 		$1.63M Buy
39,480
+17,612
+81% +$683K 0.01% 945
2025
Q3 		$861K Buy
+21,868
New +$559K ﹤0.01% 1056

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Voloridge Investment Management's DNTH Position: Q1 2026 in Review

Voloridge Investment Management sold out of Dianthus Therapeutics (DNTH) in Q1 2026, closing a stake of 39,480 shares — an estimated $1.63M sold.

Voloridge Investment Management first reported a position in DNTH in Q3 2025 and held it in 2 quarters. The position peaked at $1.63M in Q4 2025. 241 funds tracked by Wall St. Rank hold DNTH as of Q1 2026.

  • Voloridge Investment Management reported no remaining Dianthus Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Voloridge Investment Management sold 39,480 Dianthus Therapeutics shares in Q1 2026, an estimated $1.63M.
  • Voloridge Investment Management first reported a position in Dianthus Therapeutics in Q3 2025 and held it in 2 quarters.
  • Voloridge Investment Management's Dianthus Therapeutics position peaked at $1.63M in Q4 2025.
  • 241 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q1 2026.

Based on Voloridge Investment Management's 13F filing for Q1 2026, filed 15 May 2026.